Rituximab was used to treat recurrent IgG4-related hypophysitis with ophthalmopathy as the initial presentation
A case report and literature review

Wei-Jun Gu, MD
Qian Zhang, MD
Jian Zhu, MD
Jie Li, MD
Shi-Hui Wei, MD
Yi-Ming Mu, MD

Abstract

**Rationale:** Immunoglobulin G4 (IgG4)-related hypophysitis is a type of IgG4-related disease (IgG4-RD), which is characterized by plasma cells infiltration in the pituitary causing functional changes and (or) space-occupying effect in the pituitary. IgG4-related hypophysitis is sensitive to hormone therapy in most patients, but recurrence is very likely.

**Patient concerns:** Here, we report a 57-year-old male patient with bilateral eye redness as the initial presentation. He later presented with pituitary hypofunction that involved multiple organs, including eyes, lacrimal gland, pituitary, lung, gall bladder, and intestine. There was an elevation of C-reactive protein and blood sedimentation, but the IgG and IgG4 levels of the serum and the cerebrospinal fluid did not increase obviously following irregular glucocorticoid therapy. Magnetic resonance imaging revealed enlarged pituitary and obviously thickened pituitary stalk. IgG4-related hypophysitis was confirmed by biopsy of the pituitary.

**Diagnoses:** The patient was diagnosis of IgG4-related hypophysitis with ophthalmopathy by pathological and molecular tests.

**Interventions:** The patient responded to methylprednisolone pulse therapy but relapsed during the maintenance therapy using small-dose hormones combined with azathioprine. Methylprednisolone pulse therapy was given for 3 days followed by rituximab injection for 4 weeks.

**Outcomes:** After use methylprednisolone pulse therapy with rituximab the patient achieved complete remission.

**Lessons:** Rituximab achieved good effect for recurrent IgG4-related hypophysitis after glucocorticoid therapy combined with immunosuppressant in this case. Moreover, comparative analysis was carried out with other reported cases of IgG4-related hypophysitis in terms of clinical features, treatment, and follow-up.

**Abbreviations:** CRP = C-reactive protein, CT = computed tomography, IgG4 = immunoglobulin G4, IgG4-RD = IgG4-related disease, MRI = magnetic resonance imaging, PET-MRI = positron emission tomography-magnetic resonance imaging.

**Keywords:** glucocorticoid, hypophysitis, IgG4-related disease, pituitary hypofunction, rituximab

1. Introduction

IgG4-related disease (IgG4-RD) is a newly discovered autoimmune disease manifested as chronic progression of systemic inflammation and fibrosis of unknown etiology. This term was first used by Hamano et al[1] in 2001 when describing 1 case of sclerosing pancreatitis. This case attracts great attention due to the elevation of the serum IgG4 level. As found by subsequent studies, such type of patients is combined with similar lesions in other organs, including bile duct, salivary gland, orbits, lymph nodes, retroperitoneum, mediastinum, soft tissue, and nerve system.[2-11]. They are all characterized by extensive interstitial fibrosis, diffuse lymphoplasmacytic infiltration with obstructive phlebitis and significant elevation of the serum IgG4 level. If the pituitary is involved, it is known as IgG4-related hypophysitis. IgG4-related hypophysitis is featured by hypofunction of anterior pituitary and (or) diabetes insipidus. IgG4-related hypophysitis is featured by hypofunction of anterior pituitary and (or) diabetes insipidus, sometimes with space-occupying effect and multiorgan involvement. The elevated serum IgG4 level is considered an important diagnostic clue. Typical imaging findings include mass in the saddle area or thickening of pituitary stalk. The diagnosis can be confirmed by pathological examination. IgG4-related hypophysitis is usually sensitive to glucocorticoid therapy, but
recurrence is very likely. This disease is rare and the diagnosis is difficult with high misdiagnosis rate. We present 1 recurrent case of IgG4-related hypophysitis with ophthalmopathy as the initial presentation and multiorgan involvement in the hope of benefiting the understanding on IgG4-related hypophysitis.

2. Materials and methods

The 57-year-old male, who was admitted to hospital in April, had bilateral eye redness for 1 year, with poor appetite and malaise. The patient reported the onset of bilateral eye swelling 1 year ago, particularly in the right eye, which had conjunctival and scleral congestion with progressive vision loss. He responded poorly to irregular hormone therapy. Four months before hospitalization, the patient showed the symptoms of malaise, poor appetite, nausea after eating greasy food without vomiting, fear of cold, and loss of weight. He then presented with compulsive polydipsia and polyuria with daily water uptake reaching 4.5 L. Fever of unknown reason occurred 1 month ago, with body temperature of 37.3 to 38.5°C and concurrent headache. The headache was aggravated when the body temperature rose. Antibiotic therapy achieved no effect. After admission, the patient suffered from chest tightness, suffocation, and intermittent diarrhea.

3. Results

Physical examination upon admission revealed: thin skin, scattered petechiae under the skin, muscular atrophy of the 4 limbs, no facial deformity, missing of several teeth, bilateral eyelid edema, conjunctival and scleral congestion of the right eye (Fig. 1), fl exible movement of bilateral eyes on the thick side. Ophthalmologic examination revealed visual field defect and obvious visual impairment of the right eye. Auxiliary examinations revealed pituitary hypofunction, elevation of blood sedimentation and CRP, negative indicators related to tuberculosis and infections (Tables 1–3). The results were all negative for 5 antituberculosis antibodies, 6 anti-ENA antibodies and anti-cardiolipin antibodies; the tumor markers were negative; IgG 83.9mg/dL and IgG 1260.0mg/dL in peripheral blood (Table 4); IgG 12.5mg/dL, IgA 1.16mg/dL, and IgM 0.21mg/dL in the cerebrospinal fluid (Table 5). Smears showed no fungi or bacteria; negative for Hu Yo Ri and antigens. Only a few lymphocytes without cancer cells were observed in pathological examination. MRI indicated space-occupying lesions in the saddle area and the basilar clivus as well as cysts in the pituitary stalk (Fig. 2); MRI of the orbits indicated inflammatory lesion of the right eye (Fig. 3); chest CT scan revealed bilateral lung nodules suspected as granulomas (Fig. 4). PET-MRI indicated

Table 1
Gonadal hormone concentrations.

|           | On admission | After methylprednisolone impulse therapy | Disease recurrence | After matthera therapy |
|-----------|--------------|----------------------------------------|-------------------|------------------------|
| T (8.4–28.7 nmol/L) | <0.35         | 3.48                                   | 6.72              | 3.76                   |
| E2 (<353.1 pmol/L) | <43.31         | 84.8                                   | <43.31            | 92.57                  |
| LH (1.5–9.3 mU/mL) | 0.37          | 5.08                                   | 4.53              | 3.87                   |
| FSH (1.4–18.1 IU/L) | 2.75          | 8.24                                   | 9.76              | 10.34                  |
| PRL (2.1–17.7 ug/L) | 7.37          | 6.85                                   | 21.21             | 17.95                  |
| P (0.89–3.88 remo/L) | <.48          | <.48                                   | <.48              | <.48                   |

Table 2
LH and FSH value (basal and response to intravenous injection of 100 ug gonadotropin-releasing hormone) before treatment.

| Time (min) | 15 | 30 | 60 | 120 |
|------------|----|----|----|-----|
| LH, IU/L   | <0.07 | 0.07 | 6.72 | 12.71 | 12.56 |
| FSH, IU/L  | 1.86 | 1.67 | 5.12 | 10.02 | 12.09 |

Table 3
Thyroid function.

|       | On admission (before euthyrox therapy) | After methylprednisolone impulse therapy (with euthyrox 75 μg/d) | Disease recurrence (with euthyrox 75 μg/d) | After matthera therapy (with euthyrox 75 μg/d) | Normal range |
|-------|---------------------------------------|---------------------------------------------------------------|---------------------------------------------|------------------------------------------------|--------------|
| T4, nmol/L | 53.4                                   | 88.0                                                          | 129.5                                       | 82.7                                            | 55.34–160.88 |
| T3, nmol/L | 0.49                                   | 0.84                                                          | 1.49                                        | 0.89                                            | 1.01–2.95   |
| FT3, pmol/L | 2.43                                   | 2.87                                                          | 4.32                                        | 3.09                                            | 2.76–6.3    |
| FT4, pmol/L | 7.56                                   | 13.51                                                         | 16.82                                       | 16.14                                           | 10.42–24.32 |
| TSH, mIU/L | 0.02                                   | 0.03                                                          | 0.29                                        | 0.04                                            | 0.35–5.5    |
multorgan involvement, that is, systemic inflammatory lesions intracranially, in the right salivary gland, sinus nasalis, chest and paravertebrally, gall bladder, colon, and rectum. Under the navigation of MRI, biopsy of the saddle area was performed via the transspHENoidal approach and IgG4-related hypophysitis (Fig. 5) was confirmed. The patient was sensitive to methylprednisolone pulse therapy at 36 mg/d for 4 weeks. The symptoms of headache, ophthalmopathy (Fig. 1), chest tightness, and diarrhea were alleviated obviously. But the pituitary function was not improved. Therefore, Euthyrox and Minirin replacement therapy was given. The dose of methylprednisolone was decreased at the rate of 4 mg per 2 weeks until 8 mg/d, and maintenance therapy was given along with azathioprine at 100 mg/d. The patient relapsed 4 months later, showing such symptoms again as headache, bilateral eye redness, and swelling (particularly in the right eye), and vision impairment (Fig. 2). Methylprednisolone pulse therapy was given at 600 mg/d for 3 days, followed by rituximab injection at 100 mg/wk for 4 weeks. The patient achieved complete remission (Figs. 1 and 2).

Hypophysitis is featured by inflammation and cell infiltration of the pituitary. Depending on the position involved, hypophysitis is divided into panhypophysitis, adenohypophysitis, and infundibulo-hypophysitis. In terms of histopathology, hypophysitis is divided into lymphocytic hypophysitis, granulomatous hypophysitis, xanthomatous hypophysitis, necrotizing hypophysitis, IgG4-related hypophysitis, and mixed hypophysitis. By etiology, hypophysitis is either primary or secondary.\(^4\)

We report 1 case of IgG4-related hypophysitis, which is very rare clinically. IgG4-related hypophysitis is part of the IgG4-related disease, which was first described by van der Vliet and Pernis\(^5\) in 2004. Wong et al\(^6\) produced the first pathological diagnosis of this disease. The diagnostic criteria were proposed in 2011 by Leporati et al (Table 6).\(^7\) Our patient met the criteria 2, 3, and 5.

IgG4-related disease involving the central nervous system is rare. According to the existing reports, the disease is confined in the pituitary. So far 46 cases of IgG4-related disease have been reported, and most of them are from Japan. There are 36 males (78.3%) and 10 females (21.7%), with the age of onset being 25 to 81 years, 63 years on average; 4 cases (8.7%) are affected in the saddle area, 8 (19.6%) in the pituitary stalk, and 33 (71.7%) in the saddle area as well as the pituitary stalk; 10 cases (22.2%) have hypofunction of anterior pituitary, 6 (13.3) have diabetes insipidus, 310 mosm/L) 130.5 138.3 100 IU/mL) 103.0 60.5 39.0 24.5

| Parameter          | On admission | After methylprednisolone impulse therapy | Disease recurrence | After mabthera therapy |
|--------------------|--------------|------------------------------------------|--------------------|------------------------|
| IGF-1 (81–225)     | 95.4         | 82.9                                     | 123                |                        |
| Blood osmotic pressure (275–310 mosm/L) | 307          | 289                                      | 304                | 309                    |
| Urine osmotic pressure (400–1200 mosm/L) | 173          | 274                                      | 498                |                        |
| CRP (0–0.8 mg/dL)  | 7.9          | 1.62                                     | 7.93               | 0.698                  |
| ESR (0–20 mm/h)    | 87           | 11                                       | 66                 | 1                      |
| Sodium (130–150 mmol/L) | 130.5    | 138.3                                    |                     |                        |
| Potassium (3.5–5.0 mmol/L) | 3.48    | 3.7                                      | 4.09               |                        |
| Complement C4 (10–40 mg/dL) | 42.3    | 23.7                                     | 31.2               | 24.4                   |
| IgA (70–400 mg/dL) | 177.0       | 150.0                                    | 159.0              | 107.0                  |
| IgE (0–100 IU/mL)  | 103.0        | 60.5                                     | 39.0               | 24.5                   |
| IgG (700–1600 mg/dL) | 1260.0      | 780.0                                    | 1160.0             | 705.0                  |
| IgM (40–230 mg/dL) | 81.2         | 48.1                                     | 71.4               | 56.9                   |
| IgG1 (405–1011 mg/dL) | 651        | 500.0                                    | 651.0              | 421.0                  |
| IgG2 (169–786 mg/dL) | 516         | 201.0                                    | 428.0              | 300.0                  |
| IgG3 (11–85 mg/dL) | 62.3         | 110.0                                    | 90.7               | 35.2                   |
| IgG4 (3–201 mg/dL) | 83.9         | 71.3                                     | 63.5               | 26.3                   |

CRP = C-reactive protein.

Table 4

| Parameter          | On admission | After methylprednisolone impulse therapy | Disease recurrence | After mabthera therapy |
|--------------------|--------------|------------------------------------------|--------------------|------------------------|
| IGF-1 (81–225)     | 95.4         | 82.9                                     | 123                |                        |
| Blood osmotic pressure (275–310 mosm/L) | 307          | 289                                      | 304                | 309                    |
| Urine osmotic pressure (400–1200 mosm/L) | 173          | 274                                      | 498                |                        |

**Discussion and conclusions**

The distinguishing features of IgG4-related disease are the elevation of serum IgG4 level and infiltration by IgG4-positive
plasma cells. For pituitary tumors of unknown etiology, we recommend detection of serum IgG4 level before the glucocorticoid therapy. Although elevated serum level of IgG4 is an important diagnostic indicator of IgG4-related hypophysitis, it is neither a necessary nor specific one. In our case, the serum IgG4 level was detected after irregular glucocorticoid therapy and the result was lower than 140 mg/dL, which did not reach the diagnostic criterion. Moreover, among 46 cases of IgG4-related hypophysitis.
hypophysitis, 10 cases had serum IgG4 level lower than the criterion after glucocorticoid therapy. This indicated the role of glucocorticoid therapy in reducing the serum level of IgG4. Tabata et al. detected the changes of serum IgG4 level in 44 cases of IgG4-related disease and proposed that the serum IgG4 level can be a predictor of the relapse.

In the absence of contraindications, glucocorticoid is the first-line drug for inducing remission for patients at early active phase of the disease. The initial dose of prednisone is usually 30 to 40 mg/d (0.6 mg/kg) and the dose can be increased for higher body weight or rapid progression. For milder symptoms, small initial dose can be used. After 2 to 4 weeks, the dose can be reduced to the dose of maintenance therapy (5.0–7.5 mg/d) at the rate of 5 mg every 2 weeks. The small-dose maintenance therapy can sometimes last for 3 years. Although hormone therapy is effective, relapse may be induced by drug disuse (30–45%). Therefore, immunosuppressant can be prescribed in combination, including azathioprine, methotrexate, mycophenolate mofetil, and cyclophosphamide. The immunosuppressant is necessary for the starting therapy in some patients. In case of relapse, glucocorticoid pulse therapy and maintenance therapy can be still applied. The present case evolved into multiorgan involvement after irregular glucocorticoid therapy with symptom aggravation. The symptoms of eyes, lung, intestine, and headache were greatly relieved after pulsed therapy using methylprednisolone at 36 mg/d for 4 weeks. MRI revealed reduced pituitary as compared with before, but without functional recovery. Considering the long course of disease and severity of the symptoms, methylprednisolone 8 mg/d combined with azathioprine 100 mg/d was used, but the patient relapsed several months later. After methylprednisolone pulse therapy at 600 mg/d for 3 days, rituximab injection was performed and good effect was achieved. So far only 6 recurrent cases of IgG4-related hypophysitis have been reported, and all of them are males aged 40 to 75 years; 4 cases are combined with lesions of other organs. The glucocorticoid therapy for recurrent patients consists of prednisone 30 mg/d, 10 mg/d, 7.5 mg/d, 5 mg/d or hydrocortisone. Recurrent patients may suffer from headache, visual field defect, and reduced pituitary function. Five cases were relieved by the regimen of first increasing and then decreasing the dose of prednisone; another case was relieved by the use of azathioprine on the basis of prednisone. However, all 6 cases failed to achieve functional recovery of the pituitary. Our case was the first case of IgG4-related hypophysitis who achieved complete remission after relapse by rituximab injection. This indicated the superiority of rituximab as a maintenance and remedial therapy compared
with hormone therapy and immunosuppressants. Hart et al. carried out a follow-up study that lasted for 47 months. One group of recurrent patients was treated by prednisone, and the other group by hormone therapy combined with immunosuppressant. Two groups did not show significant difference at the time of remission. Besides, the failure rate of immunosuppressant was as high as 48%. In contrast, rituximab injection exhibits better effect in resistant to immunosuppressant and intolerant to hormone. Long-term remission was achieved in 83% of the patients with resistance to hormone and (or) immunosuppressant after rituximab injection. They did not relapse during the maintenance therapy, and presented with no obvious adverse events. So far we have no available data of large-sample follow-up of IgG4-related hypophysitis. Most patients can achieve rapid remission after hormone therapy, but others require long-term hormone replacement therapy with good prognosis. The major prognostic factors are the time of diagnosis and multiorgan involvement.

IgG4-related hypophysitis is presented as functional damage and space-occupying lesion in the pituitary, probably with involvement of other organs. Some patients may be first diagnosed due to symptoms of the affected organs as the initial presentation, such as pancreatitis, cholangitis, and pneumonia. We report 1 case of IgG4-related hypophysitis with ophthalmopathy as the initial presentation. This case was combined with multiorgan involvement and relieved by glucocorticoid therapy combined with immunosuppressant. Later the case relapsed and achieved complete remission by rituximab injection. For patients with IgG4-related hypophysitis, not only hypophysitis, but also the involvement of other organs deserves evaluation before the formulation of treatment regimen. Long-term follow-up is preferred.

**Table 6**

| Diagnostic criteria for IgG4-related hypophysitis. |
|--------------------------------------------------|
| Criterion 1: Pituitary histopathology              |
| The pituitary is infiltrated by numerous lymphocytes and plasma cells, with over 10 IgG4-positive cells in each high power field |
| Criterion 2: Pituitary MRI                         |
| Space-occupying lesion in the saddle area and (or) thickening of pituitary stalk. |
| Criterion 3: Biopsies of other organs              |
| Confirmed as IgG4-related disease                 |
| Criterion 4: Serology                             |
| Elevated serum level of IgG4 (>140 mg/dL)        |
| Criterion 5: Response to glucocorticoids          |
| High sensitivity to glucocorticoid therapy, with rapid disappearance of space-occupying lesion of the pituitary and improved symptoms |

Diagnosis of IgG4-related hypophysitis is established when any of the following is fulfilled:
- Criterion 1 OR
- Criterion 2 and 3 OR
- Criterion 2, 4 and 5

MRI = magnetic resonance imaging.

**References**

[1] Hamano H, Kawa S, Horiuchi A, et al. High serum IgG4 concentrations in patients with sclerosing pancreatitis. N Engl J Med 2001;344:732-8.
[2] Hamano H, Kawa S, Horiuchi A, et al. High serum IgG4 concentrations in patients with sclerosing pancreatitis. N Engl J Med 2001;344:732-8.
[3] Cheuk W, Chan JK. IgG4-related sclerosing disease: a critical appraisal of an evolving clinico-pathologic entity. Adv Anat Pathol 2010;17:303-32.
[4] Caturegli P, Newschaffer C, Olivi A, et al. Autoimmune hypophysitis. Endocr Rev 2005;26:599-614.
[5] van der Vliet HJ, Perenboom RM. Multiple pseudotumors in IgG4-associated multifocal systemic fibrosis. Ann Intern Med 2004;141:896-7.
[6] Wong S, Lam WY, Wong WK, et al. Hypophysitis presented as inflammatory pseudotumor in immunoglobulin G4-related systemic disease. Hum Pathol 2007;38:1720-3.
